{"article_link": "https://doi.org/10.1038/s41467-023-42565-z", "data": [{"id": "data_1", "omics": "Epigenomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "BAM, FASTQ", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA002815"}, {"id": "data_2", "omics": "Transcriptomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "BAM, FASTQ", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA000119"}, {"id": "data_3", "omics": "Genomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "VCF", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA005668"}, {"id": "data_4", "omics": "Chromatin Immunoprecipitation Sequencing (ChIP-seq)", "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122989", "format": "BAM", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE122989"}, {"id": "data_5", "omics": "Chromatin Immunoprecipitation Sequencing (ChIP-seq)", "link": "https://ega-archive.org/", "format": "BAM", "source": "European Genome-phenome Archive (EGA)", "public_id": "EGAD00001002421"}, {"id": "data_6", "omics": "Transcriptomics", "link": "https://depmap.org/portal/download", "format": "TXT", "source": "DepMap", "public_id": "DepMap Public 21Q1"}, {"id": "data_7", "omics": "Drug Response", "link": "https://depmap.org/portal/download", "format": "TXT", "source": "DepMap", "public_id": "Drug sensitivity AUC (CTD^2)"}, {"id": "data_8", "omics": "Genomics", "link": "https://gdc.cancer.gov/about-data/publications#/?groups=TARGET-ALL-P2&years=&order=desc", "format": "VCF", "source": "TARGET", "public_id": "phs000464"}], "analyses": [{"id": "analysis_1", "analysis_type": "chromatin accessibility profiling", "analysis_data": ["data_1"], "training_set": null, "test_set": null, "label": {"condition": ["relapsed B-ALL"]}}, {"id": "analysis_2", "analysis_type": "comparison", "analysis_data": ["data_1", "data_4"], "training_set": null, "test_set": null, "label": {"conditions": ["B-ALL", "B-cell progenitors"]}}, {"id": "analysis_3", "analysis_type": "subtyping", "analysis_data": ["data_1"], "training_set": null, "test_set": null, "label": {"subtypes": ["hyperdiploidy", "ETV6::RUNX1", "TCF3::PBX1", "KMT2A rearranged", "BCR::ABL1", "BCR::ABL1-like", "ZNF384", "PAX5alt", "TCF3::HLF", "hypodiploidy", "MEF2D", "B-other"]}}, {"id": "analysis_4", "analysis_type": "allele-specific analysis", "analysis_data": ["data_1", "data_3"], "training_set": null, "test_set": null, "label": {"snps": ["rs7090445 (ARID5B promoter, RUNX3 binding disruption)", "rs13401811 (BCL2L11 enhancer, apoptosis-related)"]}}, {"id": "analysis_5", "analysis_type": "differential analysis", "analysis_data": ["data_1"], "training_set": null, "test_set": null, "label": {"conditions": ["diagnosis", "relapse"]}}, {"id": "analysis_6", "analysis_type": "survival analysis", "analysis_data": ["data_1", "data_8"], "training_set": null, "test_set": null, "label": {"groups": ["Group A (good prognosis)", "Group B (poor prognosis)"]}}, {"id": "analysis_7", "analysis_type": "gene regulation", "analysis_data": ["data_1", "data_2"], "training_set": null, "test_set": null, "label": null}, {"id": "analysis_8", "analysis_type": "enrichment analysis", "analysis_data": ["data_6", "data_7"], "training_set": null, "test_set": null, "label": {"category": "drug_response_genes"}}, {"id": "analysis_9", "analysis_type": "motif analysis", "analysis_data": ["data_1", "data_2"], "training_set": null, "test_set": null, "label": {"tf_clusters": ["E2F6", "RUNX1", "SALL4"]}}, {"id": "analysis_10", "analysis_type": "survival analysis", "analysis_data": ["data_1", "data_8"], "training_set": null, "test_set": null, "label": {"clusters": ["Cluster 3 (poor prognosis)"]}}], "results": [{"analysis_id": "analysis_1", "metric": "count", "value": "138,366 (median), ranging from 57,941 to 204,563", "features": ["Quies ACRs (27.95%)", "Enh ACRs (31.30%)", "IL7R promoter ACRs", "MYC enhancer ACRs"]}, {"analysis_id": "analysis_2", "metric": "overlap_percentage", "value": "98.57% (pre-pro B cells), 98.35% (pro B cells)", "features": ["IL7R promoter ACRs", "TCL1A enhancer ACRs", "MYC enhancer ACRs"]}, {"analysis_id": "analysis_3", "metric": "count", "value": "17,981 subtype-specific ACRs", "features": ["ETV6::RUNX1: E2F6-targeted ACRs", "Hyperdiploidy: stem cell/myeloid progenitor-like ACRs", "BCR::ABL1: tyrosine kinase inhibitor-responsive ACRs"]}, {"analysis_id": "analysis_4", "metric": "percentage", "value": "14.39% (median) ASOC regions", "features": ["rs7090445 (ARID5B promoter, RUNX3 binding disruption)", "rs13401811 (BCL2L11 enhancer, apoptosis-related)"]}, {"analysis_id": "analysis_5", "metric": "count", "value": "5911 relapse-high ACRs (0.95%), 1423 relapse-low ACRs (0.23%)", "features": ["Cyclophosphamide-responsive ACRs (1.54% shared)", "Doxorubicin-responsive ACRs (0.14% shared)"]}, {"analysis_id": "analysis_6", "metric": "shared_percentage", "value": "1.54% (relapse-high ACRs), 0.14% (relapse-low ACRs)", "features": ["ETV6::RUNX1-Hyperdiploidy shared ACRs", "KMT2A-BCR::ABL1 shared ACRs"]}, {"analysis_id": "analysis_7", "metric": "correlation_count", "value": "116,307 ACR-gene correlations", "features": ["CDH1", "ITGB1", "drug response genes (e.g., ABCB1, ABCG2)"]}, {"analysis_id": "analysis_8", "metric": "enrichment_p_value", "value": "Imatinib (p = 0.0029), Etoposide (p = 0.0184), Doxorubicin (p = 0.0167)", "features": ["BCR::ABL1: Imatinib/Dasatinib targets", "ETV6::RUNX1: Doxorubicin resistance"]}, {"analysis_id": "analysis_9", "metric": "enrichment_score", "value": "109 TFs with subtype-specific motifs", "features": ["E2F6 (ETV6::RUNX1-specific)", "RUNX1 (BCR::ABL1-specific)", "SALL4 (KMT2A-specific)"]}, {"analysis_id": "analysis_10", "metric": "survival_p_value", "value": "EFS p = 0.0012, OS p = 0.0002", "features": ["Cluster 3: 3 hyperdiploidy cases with myeloid-like ACRs", "Hyperdiploidy Group B: 3 cases with inferior RFS"]}]}